Shares of Marinus Pharmaceuticals (MRNS) jumped after the pharma company reported positive data from the Phase 2 ganaxolone clinical trial in women with postpartum depression (PPD). The announcement excited the investors and sent the stock upwards by 18% in the pre-market trading session. However, the stock lost the initial momentum and opened up 10% when it started trading in today’s regular session.
Marinus stated that ganaxolone, its clinical stage drug, was safe and well-tolerated in all dose groups during the trial. The company added that there were no serious adverse events reported and no discontinuations due to a treatment-related adverse event.
Based on the clinical results, Marinus plans to advance the studies into the next phase of development to evaluate ganaxolone IV and oral dose regimens. The company also expects to present the data from these studies in 1H19.
Postpartum depression is a mood disorder that affects about 15% of women within the first year following childbirth. Common symptoms include feelings of extreme sadness, hopelessness, suicidal ideation, anxiety and fatigue. So far there are no approved treatments for PPD, but the most common treatments are psychotherapy and antidepressants.
Last Tuesday, the Radnor, Pennsylvania-based pharma company, presented data from its ganaxolone Phase 2 clinical trial for the treatment of pediatric genetic epilepsies at the American Epilepsy Society (AES) Annual Meeting. Marinus stated that ganaxolone showed sustained, long-term effectiveness in treating children with CDD, a refractory form of pediatric epilepsy.
MRNS stock had dropped 25% in the past three months and 40% in the past one year. The stock closed down 2.64% at $5.17 on Friday.
Target Corporation (NYSE: TGT) reported fourth-quarter 2020 financial results before the opening bell today. The department store chain reported Q4 revenue of $28.3 billion, up 21% year-over-year and higher than
Autodesk, Inc. (NASDAQ: ADSK) today reported its fourth quarter financial results for the period ended January 31, 2021. Net income for the fourth quarter was $911.3 million, or $4.10 per
Beyond Meat (NASDAQ: BYND), a specialist in plant-based meat substitutes, Thursday reported a wider loss for the fourth quarter, despite an increase in revenues. The numbers also missed the consensus